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ABSTRACT
Oral melphalan and prednisone remain an effective and
tolerable treatment for patients with multiple myeloma.
For approximately 40 years, this combination has been
the standard of care for patients not proceeding to stem
cell transplant. Within the last 10 years, new agents have
been found to be efficacious in the relapsed/refractory
setting. Within the last year, two trials of added thali-
domide in the newly diagnosed setting have demon-
strated outcomes superior to those achieved with
melphalan and prednisone alone. This improved out-
come comes at the cost of increased toxicity.
The National Cancer Institute of Canada Clinical
Trials Group (NCIC CTG) has recently developed a ran-
domized phase II trial (MY.11) that uses a combination
of lenalidomide with melphalan for patients with newly
diagnosed multiple myeloma. Lenalidomide is a thali-
domide analogue and, like thalidomide, is thought to
work through immunomodulatory effects. It was shown
to have activity in patients with relapsed or refractory
disease and, in combination with dexamethasone, is su-
perior to dexamethasone alone. Lenalidomide holds
promise as a more effective and potentially less toxic
derivative of thalidomide. Experience with lenalido-
mide in combination with chemotherapy is very lim-
ited, and the purpose of MY.11 is to establish tolerability
and to gain knowledge about efficacy. The information
gained from MY.11 is expected to help inform dosing
levels and schedules for a large phase III trial being
developed by the Eastern Cooperative Oncology Group
that will include participation by the NCIC CTG.
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1. INTRODUCTION
Multiple myeloma remains an incurable malignancy
that causes significant morbidity in the people affected.
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ORIGINAL ARTICLE
Although myeloma accounts for only 1.0% of all
malignancies, it accounts for approximately 13% of
hematologic neoplasms, with an average annual age-
adjusted incidence rate of 4.7 per 100,000 male popu-
lation and 3.2 per 100,000 female population 1.
Before the introduction of effective chemotherapy
with melphalan and prednisone, median overall sur-
vival in myeloma was approximately 17 months 2.
The combination of melphalan and prednisone, in-
troduced almost 40 years ago, provided an effective
and well-tolerated regimen that was, until recently,
considered the standard of care for myeloma patients
not planned for transplantation. Initial response rates
for the regimen approach 70%, but fewer than 5% of
patients achieve a complete remission. Median over-
all survival is just 3.5 years, and 35 years of testing
have failed to produce a superior chemotherapy regi-
men. But in 2006, two randomized controlled trials
were reported that demonstrated superior outcomes
in patients treated with melphalan, prednisone, and
thalidomide 3,4.
Palumbo and colleagues published the results of
a myeloma trial completed by the Italian Coopera-
tive Group. It demonstrated that, in older patients with
myeloma (median age: 72 years), the 2-year event-
free survival was superior in patients who received
100 mg thalidomide daily in addition to standard
doses of melphalan and prednisone [54% vs. 27%;
hazard ratio (HR): 0.51; 95% confidence interval (CI):
0.35 to 0.75; p = 0.0006]. Patients allocated to re-
ceive thalidomide also received that drug as mainte-
nance therapy. The trial failed to detect a difference
in overall survival (HR: 0.68; 95% CI: 0.38 to 1.22;
p = 0.19), but the trial design did not have statistical
power sufficient to address that outcome measure.
In the second trial, reported by Facon et al., the
French myeloma group completed a three-arm trial
comparing melphalan and prednisone, intermediate-
dose melphalan with stem cell support, and standard
doses of melphalan and prednisone plus thalidomide
at best tolerated dose to a maximum of 400 mg daily.
Compared with melphalan and prednisone, the sameWHITE et al.
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agents with thalidomide added improved both me-
dian progression-free survival (29.5 months vs.
17.5 months, p < 0.001) and overall survival (not
reached vs. 30.3 months, p = 0.0008).
The results from these two trials have made the
combination of melphalan, prednisone, and thalido-
mide the standard of care for previously untreated
patients with myeloma who are not candidates for
autologous transplantation. Access to thalidomide in
Canada and cost of the drug in Canada and in other
countries remain barriers to common first-line use of
this new combination.
In two randomized trials, the use of high-dose
melphalan supported by blood stem cell transplanta-
tion was demonstrated to confer a survival advan-
tage in younger patients 5,6. Consistent results from
other randomized trials comparing transplantation
with standard-dose chemotherapy have not been ob-
served: two recently published trials failed to detect
differences in important outcomes 7,8. Nevertheless,
transplantation remains a standard option that is lim-
ited to younger patients who are able to tolerate dose-
intensive therapy. Standard-dose therapy with
melphalan, prednisone—and now thalidomide—is
generally considered for patients of more advanced
age or with comorbid illnesses.
Immunomodulatory drugs are a recent discovery
in the treatment of myeloma. They have shown re-
markable anti-myeloma activity, particularly in the
setting of relapsed or refractory disease. Thalidomide,
the prototype of this group, was originally proposed
to have an antitumour effect through inhibition of
angiogenesis; more recent data suggest that the
antitumour effect is mediated through several diverse
mechanisms 9.
Side effects with thalidomide include mild to
moderate constipation, neuropathy, or somnolence in
at least one third of patients 10. In addition, thalido-
mide has been associated with risks of venous throm-
boembolism. Thus, testing of thalidomide analogues
that have at least similar, if not superior, efficacy and
a safer toxicity profile is desirable.
2. DISCUSSION
2.1 Lenalidomide in the Treatment of Myeloma
Lenalidomide is a derivative of thalidomide that has
demonstrated anti-myeloma activity in phase I and II
studies evaluating patients with relapsed or refrac-
tory disease. Lenalidomide is not associated with
significant constipation, neuropathy, or somno-
lence 11–13. In addition, in a randomized trial evaluat-
ing patients with relapsed myeloma, a comparison of
dexamethasone and lenalidomide with dexametha-
sone and placebo showed that patients in the lena-
lidomide-containing arm had superior outcomes even
if they had received prior thalidomide 14. These data
suggest that, at a minimum, lenalidomide has some
degree of non-cross-reactivity with thalidomide or
potential as a more potent anti-myeloma agent. The
drug therefore holds promise as an orally available,
more effective, and less toxic derivative of thalido-
mide for the treatment of multiple myeloma.
2.2 The National Cancer Institute of Canada
Clinical Trials Group MY.11 Trial
The experience evaluating lenalidomide in combi-
nation with melphalan has been limited, although both
drugs have now been shown to be effective therapy
in patients with myeloma. To evaluate the combina-
tion of these agents and to investigate the possibility
of improved response rates and progression-free sur-
vival for previously untreated patients, the National
Cancer Institute of Canada Clinical Trials Group (NCIC
CTG) has developed a phase II trial, MY.11, that uses
a combination of lenalidomide and melphalan in
newly diagnosed patients. The tolerable dose of
lenalidomide in combination with melphalan is not
known. Because the expected toxicity of lenalidomide
is myelosuppression, both short-term (cycles 1 and 2)
and, just as importantly, longer-term (cycles 3–6 and
possibly beyond) cumulative myelosuppression must
be assessed to optimize the tolerable dose of
lenalidomide and to maximize the potential for suc-
cess of combination therapy in phase III testing.
Other groups will be conducting traditional
phase I trials with short-term toxicity endpoints, but
NCIC CTG believes that longer-term ability to deliver
melphalan is also likely to be critical in the phase III
setting, and that the best way to establish tolerability
over multiple cycles, while gaining valuable infor-
mation about the efficacy of the combination, is to
conduct a trial using a randomized phase II design.
The induction phase in the MY.11 study therefore
uses a randomized phase II design to investigate the
effect of using lenalidomide in combination with
melphalan as initial therapy in patients with multiple
myeloma for whom high-dose melphalan and periph-
eral blood stem cell transplantation is not considered
appropriate by virtue of age, comorbid illness, or
patient choice. As an initial step, each arm of the pro-
posed randomized phase II trial will be tested sepa-
rately in a consecutive manner to demonstrate safety
before further testing is undertaken.
The concept of combining melphalan and
lenalidomide is an attractive one. The NCIC CTG are
aware of two other groups who are also developing
the concept.
The first is the myeloma team based at the Mayo
Clinic, who are conducting a standard phase I study
testing the addition of lenalidomide to the combina-
tion of melphalan and prednisone. Preliminary reports
suggest that 5 mg/m2 melphalan and 60 mg/m2 pred-
nisone daily for 4 days plus 10 mg lenalidomide on
days 1–21 in a 28-day cycle will subsequently be
tested in a phase II trial 15.NCIC CTG MY.11 TRIAL
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The second group of investigators, from Italy, is
led by Palumbo. This group is conducting a phase I
study testing the addition of lenalidomide to the com-
bination of melphalan and prednisone. The most re-
cent update of this trial 16 reported the outcomes of
50 patients enrolled into four dose levels. The first
two dose levels combine lenalidomide 5 mg daily for
21 days every 4–6 weeks with melphalan 0.18 mg/kg
or 0.25 mg/kg given daily for 4 days. No dose-limit-
ing toxicities have been observed.
In a third dose level that is testing lenalidomide
10 mg and melphalan 0.18 mg/kg, one dose-limiting
toxicity (neutropenia) has been observed in the first
21 patients. Granulocyte colony stimulating factor
(G-CSF) was frequently required, and even with G-CSF
support, dose delays and attenuations were frequent.
The overall response rate observed has been 100%,
and 24% of patients achieved a complete remission.
A fourth dose level of melphalan 0.25 mg/kg and
lenalidomide 10 mg is also being tested. At those
doses,  G-CSF use and dose attenuations and delays have
been more common. The overall response rate is
100%, and the complete remission rate is 10%.
Final determination of the data for the use of these
agents remains to be completed, but the preferred
doses are likely to be melphalan 0.18 mg/kg and
lenalidomide 10 mg. That dose of melphalan trans-
lates to 7 mg/m2, pending the body habitus of the
patient. Based on the preliminary data, use of these
doses would anticipate regular use of G-CSF to reduce
the risks associated with profound neutropenia and
to maintain the treatment schedule.
The initial intent of NCIC CTG was to compare the
standard dose of melphalan (9 mg/m2 daily for 4 days
every 28 days) combined with lenalidomide at either
10 mg or 20 mg daily for 21 days every 28 days, with
each arm to be tested in separate and consecutive
safety run-ins in 6 patients before the randomized
portion of the trial commenced. The MY.11 protocol
was activated in December 2005, and by April 2006,
4 patients had been enrolled and had received their
first cycles of therapy. Based on dose-limiting toxic-
ity seen in the first 4 patients evaluated at the 10-mg
lenalidomide dose, and taking into account the emerg-
ing data described above, accrual to the initial treat-
ment protocol was suspended, and the drug doses
redefined. The revisions now include reduced doses
of melphalan and of lenalidomide, and a new, more
restrictive, dose attenuation schedule that begins with
dose attenuations on day 8 of each treatment cycle if
features of myelosuppression are noted at that time.
In addition, the eligibility criteria for the trial have
been modified, and now include a need for normal
platelet count upon study entry. The additional data
from the Italian group indicate a high likelihood of
initial tolerability of the new doses to be tested.
The revised MY.11 study will test two new dose
levels of melphalan plus lenalidomide. The aims are
to determine doses that can be safely administered
without routine use of G-CSF and to obtain estimates
of efficacy that would justify proceeding to a ran-
domized trial comparing this combination with the
combination of melphalan, prednisone, and thalido-
mide. The MY.11 trial will be a randomized multi-
centre, open-label, dose-finding, phase II study testing
two dose levels of lenalidomide plus melphalan.
In one arm of the trial, lenalidomide 15 mg daily
will be given on days 1–21 of each 28-day cycle in
combination with melphalan 4 mg/m2 given on
days 1–4 of each cycle. The purpose of this arm is to
test what NCIC CTG believes to be the highest dose of
lenalidomide that can be used as part of combination
therapy. The dose of melphalan has therefore been
proportionately reduced.
In the second arm, lenalidomide 10 mg daily will
be given on days 1–21 of each 28-day cycle in com-
bination with melphalan 6 mg/m2 given on days 1–4
of each cycle. This dose level is lower than that suc-
cessfully tested by Palumbo (melphalan 0.18 mg/kg
and lenalidomide 10 mg), but at the dose level used
by Palumbo’s group, G-CSF support was frequently
required when those doses were tested. If dose-limit-
ing toxicities are seen with lenalidomide 10 mg daily
and melphalan 6 mg/m2, the dose of melphalan will
be reduced to 5 mg/m2 in subsequent patients evalu-
ated. The purpose of this arm is to further test a lower
dose of lenalidomide with a proportionately higher
dose of melphalan. Dose reductions of lenalidomide
will be permitted beginning with cycle 1, and dose
adjustments of melphalan will be allowed beginning
with cycle 2. We believe that testing of these doses
will complement the Italian trail and will provide,
with a higher level of confidence, the optimum doses
for phase III testing.
In NCIC  CTG MY.7, a trial of standard-dose
melphalan and prednisone, 31% of patients received
a reduced dose of melphalan during cycle 2 or 3 of
the drug. The myelosuppression of the combination
of melphalan and lenalidomide is expected to be cu-
mulative. Because melphalan is the accepted stan-
dard agent in the treatment of myeloma, maintaining
the dose intensity of melphalan within an acceptable
range when it is part of a combination is desirable.
Given the apparently potent efficacy of lenalidomide
and the potential for a dose–response relationship with
this agent, the need to reduce the dose of melphalan
from its standard 9 mg/m2 to 6 mg/m2 (with lenal-
idomide 10 mg) or to 4 mg/m 2 (with lenalidomide
15 mg) appears to be appropriate. The MY.11 study
will therefore be powered so that, for each starting
dose of lenalidomide, the combination will have no
further interest if the rate of dose reduction of
melphalan or discontinuation of lenalidomide in
cycle 2 or 3 is greater than 50%. Dose reductions of
lenalidomide for hematologic toxicity will be permit-
ted and will not be considered as dose-limiting tox-
icities unless associated with dose reductions of
melphalan. The analysis of each treatment arm willWHITE et al.
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then be intent-to-treat, based on each of the two dose
levels.
Recent reports from the Southwest Oncology Group
indicate that use of prednisone at a dose of 50 mg on
alternate days significantly affects disease-free and
overall survival after standard-dose chemotherapy, with
minimal toxicity 17. Specifically, disease-free survival
improved from 6 months to 13 months and overall sur-
vival improved from 28 months to 43 months in
126 randomized patients. Similarly, dexamethasone
maintenance is also of benefit as shown in NCIC CTG
MY.7, which demonstrated a clear benefit in progres-
sion-free survival for patients receiving dexamethasone
maintenance therapy after melphalan and prednisone 18.
After 12 cycles, patients on the MY.11 protocol who
have completed melphalan and lenalidomide and who
have not progressed will be maintained on dexametha-
sone until progression or death and will be followed
for progression-free survival.
2.3 Immunomodulating Drugs and Venous
Thromboembolism
Treatment with thalidomide has been associated with
an increased risk of venous thromboembolism. This
risk appears to be especially present when the drug
is combined with chemotherapeutic drugs such as
melphalan and prednisone.
In the randomized trial reported by Palumbo 3,
more venous thromboembolism was observed in pa-
tients randomized to melphalan, prednisone, and
thalidomide than in those randomized to melphalan
and prednisone alone (12% vs. 2%, p = 0.001). This
observation resulted in a protocol amendment part-
way through the period of patient accrual to mandate
the use of enoxaparin.
Similarly, data from randomized trials have noted
an increased risk of venous thromboembolism in pa-
tients treated with lenalidomide, including a potential
increase in this risk when lenalidomide is combined
with corticosteroids. For instance, in a randomized trial
comparing lenalidomide plus dexamethasone with
dexamethasone alone, an increase in venous throm-
botic events was observed in the lenalidomide arm
(15% vs. 3.5%, p value not stated) 19.
Prophylactic therapy for venous thrombosis in
myeloma patients treated with thalidomide or
lenalidomide is therefore a topical issue. No random-
ized data are available to guide options that might
include no prophylaxis or use of aspirin, warfarin, or
heparin (fractionated or unfractionated). In the ab-
sence of such data, practice variation is observed
between investigators, with many trials now includ-
ing prophylaxis with either aspirin or low molecular
weight heparin. In the phase I trial by Palumbo and
colleagues that tested the addition of lenalidomide to
melphalan and prednisone, aspirin 100 mg was in-
cluded, and only 1 episode of venous thromboembo-
lism was observed in 50 patients 16.
Because the use of low molecular weight hepa-
rin could pose increased risk of bleeding and raises
important issues of compliance, cost, and feasibility,
treatment with aspirin may be a preferable alterna-
tive in these patients.
The role of aspirin in preventing venous throm-
boembolism is controversial. The most recent guide-
lines from an international panel recommend against
the use of aspirin as prophylaxis, in part because of
the proven superior efficacy of anticoagulation
therapy in the types of patients evaluated 20. How-
ever, other data suggest that aspirin, as compared with
placebo, may be effective in preventing venous
thromboembolism 21,22. The MY.11 trial will not have
sufficient statistical power to formally address this
question in a comparative manner. Given the con-
cerns regarding the routine use of anticoagulants in
the relevant population and also given the initial data
from Palumbo et al., NCIC CTG has chosen to include
treatment with aspirin 81 mg as part of the therapeu-
tic regimen of the pilot study.
3. SUMMARY
After many years of study and multiple clinical trials
showing no advantage of newer combinations over
melphalan and prednisone, 2006 was a very eventful
year. Two trials demonstrated improved outcomes
using melphalan, prednisone, and thalidomide. How-
ever, thalidomide is associated with many disadvan-
tages, and a great deal of interest in the thalidomide
analogue lenalidomide has arisen. Lenalidomide has
been demonstrated to be effective as a single agent
and in combination with dexamethasone. The toxic-
ity profile of lenalidomide may have advantages in
comparison with that of thalidomide. The NCIC CTG
has developed the MY.11 trial to investigate the dos-
ing profile, tolerability, and efficacy of the combina-
tion of lenalidomide and melphalan for newly
diagnosed myeloma patients. The study is designed
to examine both short- and longer-term tolerability,
and it includes the use of maintenance dexametha-
sone. With information gained from the MY.11 trial,
a tolerable dosing schedule for the combination of
melphalan and lenalidomide will be developed. That
schedule will be used, in part, to inform the dosing
levels and schedule for a phase III randomized trial
comparing melphalan, prednisone, and thalidomide
with melphalan, prednisone, and lenalidomide. The
new trial is being developed by the Eastern Coopera-
tive Oncology Group and will include participation
by NCIC CTG.
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